Approval from BPOM, Indonesia’s FDA, for clinical trial of Ivermectin in the treatment of Covid-19 patients lifted shares of Indofarma (INAF) from Rp2,070 on June 18 to Rp3,200 on Tuesday (June 29). Hype over the drug sent its price sky high whilst limited data about efficacy. To subscribe please click here
